Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/10/15  and contains information from public web pages and contributions from the ZoomInfo community.

Nikolaj Sørensen

Wrong Nikolaj Sørensen?

President and Chief Executive Off...

Phone: +46 **********  
Email: n***@***.com
Local Address: , , Sweden
Orexo AB
Virdings Alle 32 A
Uppsala , 751 05

Company Description: Orexo AB is a Sweden-based company, active within the pharmaceutical industry. The Company focuses primarily on the development of new, patented drugs by combining...   more

Employment History


  • M.Sc.
  • Master of Science , Business and Economics
105 Total References
Web References
It is a testimony that our ..., 25 June 2015 [cached]
It is a testimony that our organization in the US has reached into the core of the problem of opioid addiction enabling improved dialog with all stakeholders every day in the US on how stop the monster accidental opioid addiction," said Nikolaj Sorensen, CEO and President, Orexo AB.
Orexo: Orexo ..., 5 Feb 2013 [cached]
Orexo: Orexo strengthens the commercial leadership structure and appoints Nikolaj Sørensen as new CEO and Martin Nicklasson as Executive Chairman
Nikolaj Sørensen, currently Chief Commercial Officer of Orexo, will be promoted to CEO of the company and Martin Nicklasson, currently Chairman of the Board, will be appointed Executive Chairman, both effective as of today.
Nikolaj Sørensen will succeed Anders Lundström, who will step down as CEO of the company after successful two year tenure.
Nikolaj Sørensen has been central to this process. In order to enhance the company focus on this opportunity, the Board has decided that operations, which today primarily are directed towards support of Zubsolv, should be firmly anchored under Nikolaj Sørensen's leadership.
Nikolaj Sørensen commented "I am excited and honored to be appointed CEO of Orexo, and I look forward to closely working with Martin Nicklasson to secure the optimal commercialization for Zubsolv and Abstral in the United States."
I'm looking forward to working with Nikolaj Sørensen and the leadership team towards this common goal."
Nikolaj Sørensen joined Orexo AB in October 2011 and has focused the company's activities towards the business opportunities within the US opioid addiction market.
Nikolaj Sørensen, Chief Commercial Officer Tel: +46-703-50 78 88, Email:
Executive Management - Orexo, 20 May 2012 [cached]
Nikolaj Sørensen (born 1972) Chief Commercial Officer
M.Sc. Business and Economics. Joined in 2011.
Orexo's investments in this ..., 22 April 2015 [cached]
Orexo's investments in this follow-up study, and in planned future studies, demonstrate our continued commitment to advancing the treatment of opioid dependence for the patients suffering from this disease and providing effective and well tolerated therapies for physicians who treat them", said Nikolaj Sørensen, Chief Executive Officer of Orexo.
For further information, please contact: Nikolaj Sørensen, President and CEO Tel: +46 (0)703-50 78 88, E-mail:
Nikolaj ..., 25 June 2015 [cached]
Nikolaj Sørensen President and CEO, Orexo AB Tel: +46 (0)703-50 78 88.
Other People with the name "Sørensen":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.